Publications
Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial
Treatment outcomes remain poor in recurrent platinum-resistant ovarian cancer. Enadenotucirev, a tumor-selective and blood stable adenoviral vector, has demonstrated a manageable safety profile in phase 1 studies in epithelial solid tumors.
FORTITUDE: A phase 1 study of NG-350A, a novel tumour-selective adenoviral vector expressing an anti-CD40 agonist antibody: monotherapy dose escalation results
Aung Naing, Lee Rosen, D. Ross Camidge, Danny Khalil, Jessica Davies, David Miles, Minesh Patel, Paul Cockle, Jenny Lee, Jo Carter, Brian Champion, David Krige, Tom Lillie
Bi- and tri-valent T-cell engagers deplete tumour-associated macrophages in cancer patient samples
Eleanor M. Scott, Egon J. Jacobus, Brian Lyons, Sally Frost, Joshua D. Freedman, Arthur Dyer, Hena Khalique, William K. Taverner, Alison Carr, Brian R. Champion, Kerry D. Fisher, Len W. Seymour* and Margaret R. Duffy
An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells
JD Freedman, MR Duffy, J Lei-Rossmann, A Muntzer, EM Scott, J Hagel, L Campo, RJ Bryant, C Verrill, A Lambert, P Miller, BR Champion, LW Seymour and KD Fisher. Cancer Res 2018, 1–14, AACR.
A Phase 1 Dose Escalation Study of the Oncolytic Adenovirus Enadenotucirev, Administered Intravenously to Patients with Epithelial Solid Tumors (EVOLVE)
Jean-Pascal Machiels, Ramon Salazar, Sylvie Rottey, Ignacio Duran, Luc Dirix, Karen Geboes, Christine Wilkinson-Blanc, Gillian Pover, Simon Alvis, Brian Champion*, Kerry Fisher, Hilary McElwaine-Johnn, John Beadle and Emiliano Calvo. Journal for ImmunoTherapy of Cancer (2019) 7:20
